Reports Q3 revenue $249.3M, consensus $235.8M. “Tandem delivered a strong third quarter performance marked by record quarterly sales, significant gross margin improvement, and meaningful progress on our key strategic initiatives,” said John Sheridan, president and chief executive officer. “We are beginning to see the positive impact of our business transformation, which strengthens our ability to achieve Tandem’s near- and longer-term goals, while continuing our commitment to improve the lives of people with diabetes.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- TNDM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Tandem Diabetes Care’s New Study: A Game Changer for Type 1 Diabetes Management?
- Tandem Diabetes resumed with a Hold at Stifel
- Tandem Diabetes price target raised to $16 from $14 at Truist
- Tandem Diabetes price target raised to $15 from $11 at Citi